Eli Lilly takes a one-two punch as Covid-19 antibody combo study is halted and manufacturing ops fail inspection
An NIH trial for an Eli Lilly antibody, one of two coronavirus drugs President Trump has touted and urged the FDA to authorize in recent weeks, has been halted over a safety concern. And it is unlikely to start again for at least two weeks.
The study, known as ACTIV-3, compared the Lilly antibody plus remdesivir to the antibody plus placebo in hospitalized Covid-19 patients and was slated to enroll up to 10,000 volunteers. In a statement released late Tuesday, NIAID said that they paused the study after, in an initial sample of roughly 300 patients, one group appeared to be doing better than the other, although they did not specify which group that was.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.